INDEPENDENCE CONTRACT DRILLI (ICD) Stock Fundamental Analysis
USA - NYSE:ICD - US4534156066 - Common Stock
0.5858 USD
-0.06 (-9.88%)
0.555 USD
-0.03 (-5.26%)
We assign a fundamental rating of 1 out of 10 to ICD. ICD was compared to 61 industry peers in the Energy Equipment & Services industry. ICD may be in some trouble as it scores bad on both profitability and health. ICD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ICD had negative earnings in the past year.
In the past year ICD had a positive cash flow from operations.
In the past 5 years ICD always reported negative net income.
ICD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ICD (-15.80%) is worse than 92.06% of its industry peers.
With a Return On Equity value of -37.58%, ICD is not doing good in the industry: 87.30% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ICD has grown nicely.
ICD has a Gross Margin of 32.59%. This is in the better half of the industry: ICD outperforms 65.08% of its industry peers.
ICD's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ICD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% |
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
2. Health
2.1 Basic Checks
ICD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ICD has more shares outstanding
Compared to 5 years ago, ICD has more shares outstanding
ICD has a worse debt/assets ratio than last year.
2.2 Solvency
ICD has an Altman-Z score of -1.26. This is a bad value and indicates that ICD is not financially healthy and even has some risk of bankruptcy.
ICD has a worse Altman-Z score (-1.26) than 88.89% of its industry peers.
ICD has a debt to FCF ratio of 10.37. This is a negative value and a sign of low solvency as ICD would need 10.37 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 10.37, ICD is in line with its industry, outperforming 46.03% of the companies in the same industry.
A Debt/Equity ratio of 1.08 is on the high side and indicates that ICD has dependencies on debt financing.
ICD has a Debt to Equity ratio of 1.08. This is in the lower half of the industry: ICD underperforms 79.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Altman-Z | -1.26 |
ROIC/WACCN/A
WACC2.02%
2.3 Liquidity
A Current Ratio of 1.33 indicates that ICD should not have too much problems paying its short term obligations.
With a Current ratio value of 1.33, ICD is not doing good in the industry: 79.37% of the companies in the same industry are doing better.
ICD has a Quick Ratio of 1.28. This is a normal value and indicates that ICD is financially healthy and should not expect problems in meeting its short term obligations.
ICD has a Quick ratio of 1.28. This is in the lower half of the industry: ICD underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
The earnings per share for ICD have decreased strongly by -662.07% in the last year.
The Revenue for ICD has decreased by -21.60% in the past year. This is quite bad
ICD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.06% yearly.
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
3.2 Future
Based on estimates for the next years, ICD will show a very negative growth in Earnings Per Share. The EPS will decrease by -46.50% on average per year.
ICD is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.70% yearly.
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ICD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ICD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICD is valued a bit cheaper than the industry average as 74.60% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than ICD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.54 | ||
| EV/EBITDA | 4.69 |
4.3 Compensation for Growth
ICD's earnings are expected to decrease with -46.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ICD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.5858
-0.06 (-9.88%)
Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner Change0%
Ins Owners75.82%
Ins Owner Change0%
Market Cap8.92M
Analysts80
Price Target3.57 (509.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.38%
Min EPS beat(2)-50.58%
Max EPS beat(2)-2.18%
EPS beat(4)0
Avg EPS beat(4)-48.02%
Min EPS beat(4)-115.7%
Max EPS beat(4)-2.18%
EPS beat(8)4
Avg EPS beat(8)27.37%
EPS beat(12)5
Avg EPS beat(12)-68.42%
EPS beat(16)9
Avg EPS beat(16)-49.21%
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)2.48%
Max Revenue beat(2)10.9%
Revenue beat(4)3
Avg Revenue beat(4)3.1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)10.9%
Revenue beat(8)6
Avg Revenue beat(8)2.51%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)9
Avg Revenue beat(16)0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-48.55%
EPS NQ rev (3m)-25.02%
EPS NY rev (1m)-36.74%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-14.34%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-3.15%
Revenue NY rev (3m)-5.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.05 | ||
| P/FCF | 0.54 | ||
| P/OCF | 0.21 | ||
| P/B | 0.06 | ||
| P/tB | 0.06 | ||
| EV/EBITDA | 4.69 |
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)1.09
FCFY186.61%
OCF(TTM)2.86
OCFY487.46%
SpS11.83
BVpS10.37
TBVpS10.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% | ||
| FCFM | 9.24% |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Debt/EBITDA | 4.57 | ||
| Cap/Depr | 58.68% | ||
| Cap/Sales | 14.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 116% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | -1.26 |
F-Score3
WACC2.02%
ROIC/WACCN/A
Cap/Depr(3y)80.67%
Cap/Depr(5y)71.77%
Cap/Sales(3y)20.36%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-138.99%
EBIT growth 3YN/A
EBIT growth 5Y79.64%
EBIT Next Year42.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2030.36%
OCF growth 3Y494.79%
OCF growth 5Y30.47%